Nalaganje...

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer

Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2 directed therapies, the prognosis of HER2 amplified breast cancers has improved meaningfully. Next to monoclonal anti-HER2 antibodies and tyrosi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Mol Sci
Main Authors: Rinnerthaler, Gabriel, Gampenrieder, Simon Peter, Greil, Richard
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2019
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6429068/
https://ncbi.nlm.nih.gov/pubmed/30841523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20051115
Oznake: Označite
Brez oznak, prvi označite!